Dr. Andorsky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4715 Arapahoe Ave
Boulder, CO 80303Phone+1 303-385-2000Fax+1 303-444-1839
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
Harvard Medical SchoolClass of 2002
Certifications & Licensure
CA State Medical License 2005 - Present
CO State Medical License 2010 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
- Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- Join now to see all
Publications & Presentations
PubMed
- 54 citationsA Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative DisordersJohn M. Timmerman, John C. Byrd, David J Andorsky, Reiko E. Yamada, Janet M. Kramer
Clinical Cancer Research. 2012-10-15 - 8 citationsAsciminib in Newly Diagnosed Chronic Myeloid Leukemia.Andreas Hochhaus, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer
The New England Journal of Medicine. 2024-09-12 - 365 citationsDisabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: ...Philippe Armand, Arnon Nagler, Edie Weller, Steven M. Devine, David Avigan
Journal of Clinical Oncology. 2013-11-20
Journal Articles
- An Open‐Label Phase 2 Trial of Entospletinib in Indolent Non‐Hodgkin Lymphoma and Mantle Cell LymphomaJeff P Sharman, David J Andorsky, Christopher A Yasenchak, Kathryn S Kolibaba, British Journal of Haematology
Abstracts/Posters
- Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b StudyDavid Andorsky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.2019 ASCO Annual Meeting - 6/1/2019
- Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
US Oncology Research Announces Schedule of Presentations at the Virtual 2020 American Society of Hematology Annual Meeting and ExpositionDecember 2nd, 2020
US Oncology Research Announces Schedule of Presentations at the 2019 American Society of Hematology Annual Meeting and ExpositionDecember 5th, 2019
MAGNIFY Trial Shows Durability of Lenalidomide & RituximabNovember 10th, 2017- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
